In 2015, the global qPCR market was dominated by Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (The Netherlands), and Agilent Technologies, Inc. (U.S.). These top five market players jointly accounted for ~87.0% of the global qPCR market in 2015. Other key players in the global qPCR and dPCR market include Takara Bio, Inc. (Japan), Affymetrix Inc. (U.S.), Fluidigm Corporation (U.S.), and BioMérieux SA (France), among others.

Thermo Fisher Scientific Inc. (U.S.) held the leading position in the global dPCR and qPCR market in 2015. The company possesses a robust qPCR and dPCR product portfolio that includes key brands such as QuantStudio qPCR system, Veriti, and TaqMan reagents. The company has a strong geographic presence in more than 100 countries across the globe, with key markets in the U.S., China, Germany, and the U.K. The company mainly focuses on developing technologically advanced qPCR and dPCR products as well as reagents that are used for medical diagnostic research by clinical, pharmaceutical, industrial, and food safety laboratories. In line with this strategy, the company launched several qPCR and dPCR systems, reagents, and kits in the last three years, including QuantStudio 3 and 5, Real-time PCR system, TaqMan Assays, and qPCR MasterMixes. These product launches helped to expand the company’s existing qPCR/dPCR product portfolio and increase its revenue base in the global qPCR and dPCR market. The company also adopted inorganic growth strategies such as agreements, collaborations, and partnerships to strengthen its position in the market. In accordance with this, in January 2016, Thermo Fisher Scientific acquired Affymetrix Inc. (a U.S.-based company and leader in providing cellular and genetic analysis products) to expand the cellular and genetic analysis product market across North America.

Bio-Rad Laboratories Inc. (U.S.) held the second position in the global dPCR and qPCR market in 2015. The company possesses a well-established brand position across the life sciences and clinical diagnostics market, which includes a broad range of technologically advanced products (including qPCR and dPCR devices). To strengthen its current position and gain a larger market share, Bio-Rad Laboratories aggressively focuses on strengthening its R&D and product manufacturing capabilities for the qPCR and dPCR market. During 2013 to 2016, the company launched several innovative qPCR and dPCR devices, including the QX200 Droplet Digital PCR (ddPCR) system, PrimePCR Droplet Digital PCR (ddPCR) Assays, and CFX Automation System II (a robotic plate-handling system), among others. Moreover, the company also focuses on expanding its product distribution networks across major markets through agreements, expansions, and partnerships with key qPCR and dPCR market stakeholders.

Major strategic developments are taking place in the field of digital PCR devices and qPCR reagents. This product category is expected to witness significant growth during the study period owing to its growing application in life sciences research, clinical research, and molecular diagnostics. Several prominent qPCR and dPCR manufacturers such as Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Fluidigm Corporation, QIAGEN N.V., and Takara Bio, Inc. are focused on the development and commercialization of innovative dPCR devices, qPCR systems, and qPCR reagents to keep pace with the ongoing industry trends and to maintain their revenue base.